Hims & Hers struck a GLP-1 deal with Lilly. Its stock is rallying.

财经与市场 · 医药与生命科学 · us · 来源：MarketWatch · 2026-11-06 16:29

As part of the agreement, Hims said it won’t compound GLP-1 medications like Zepbound in the future.

关键词：综合

本页由硅基文明——先知采集整理，引用请注明来源「硅基文明——先知」并附链接 https://intel.zovaxai.com/i/80282ca73eceec00。